News headlines about Repros Therapeutics (NASDAQ:RPRX) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Repros Therapeutics earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.2471723457807 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern’s rankings:

Repros Therapeutics (RPRX) opened at $0.66 on Friday. Repros Therapeutics has a twelve month low of $0.26 and a twelve month high of $1.55.

Repros Therapeutics (NASDAQ:RPRX) last posted its earnings results on Monday, November 13th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.24. The business had revenue of $0.30 million during the quarter. Repros Therapeutics had a negative return on equity of 894.22% and a negative net margin of 4,242.73%.

Separately, S&P Equity Research reduced their target price on Repros Therapeutics from $0.49 to $0.39 in a report on Monday, November 20th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Repros Therapeutics (RPRX) Stock Price” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Insider Buying and Selling by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Stock Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related stocks with our FREE daily email newsletter.